Showing 221 - 240 results of 10,739 for search '(( 50 μ decrease ) OR ( 50 ((((ns decrease) OR (mean decrease))) OR (we decrease)) ))', query time: 0.48s Refine Results
  1. 221
  2. 222
  3. 223

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  4. 224

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  5. 225

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  6. 226

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  7. 227

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  8. 228
  9. 229
  10. 230
  11. 231
  12. 232
  13. 233
  14. 234
  15. 235
  16. 236
  17. 237
  18. 238
  19. 239
  20. 240